Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6851403 | 0.83 | KDM1A (0.33) | KDM1AKDM1B | |
| SCHEMBL246839 | 0.78 | CES2 (0.39) | DGAT1CES2CES1 | |
| SCHEMBL23205445 | 0.72 | DGAT1 (0.55) | KDM1AKDM1BDGAT1CES2CES1 | |
| SCHEMBL12273203 | 0.72 | DGAT1 (0.41) | DGAT1CES2CES1 | |
| SCHEMBL29705176 | 0.71 | AKR1C4 (0.47) | DGAT1CES2CES1 | |
| SCHEMBL366568 | 0.71 | AKR1C4 (0.47) | DGAT1CES2CES1 | |
| SCHEMBL31537517 | 0.70 | DGAT1 (0.57) | KDM1AKDM1BDGAT1CES2CES1 | |
| SCHEMBL30204393 | 0.70 | GPR27 (0.41) | KDM1AKDM1BDGAT1CES2CES1 | |
| SCHEMBL15919054 | 0.70 | KDM1A (0.37) | KDM1AKDM1BDGAT1CES2CES1 | |
| SCHEMBL12634676 | 0.70 | DGAT1 (0.38) | KDM1AKDM1BDGAT1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297120-B1 | AMINODIHYDROTHIAZINE DERIVATIVES AS BACE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | LILLY CO ELI (US) | 2015-08-19 | — | — | EP | disclosed |
| US-8877744-B2 | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8785436-B2 | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8748418-B2 | 1,4-oxazepines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-06-10 | — | — | US | disclosed |
| EP-2566855-B1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-05-21 | — | — | EP | disclosed |
| US-8673894-B2 | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20140045820-A1 | 2,5,6,7-Tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20120295900-A1 | 1,3-OXAZINES AS BACE 1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120253035-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-04 | — | — | US | disclosed |
| US-20120238548-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20110312937-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | SIENA BIOTECH S.P.A. (IT) | 2011-12-22 | — | — | US | disclosed |
| US-7648983-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2010-01-19 | — | — | US | disclosed |
| US-20090275566-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045820-A1 | 2,5,6,7-Tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds | BACE2, BACE1, PSEN2 | KDM1A 1524/4885KDM1B 753/4885DGAT1 3131/4885 |
| US-20120253035-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN2 | KDM1A 1462/4885KDM1B 836/4885DGAT1 1985/4885 |
| US-20110312937-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | BACE2, BACE1, PSEN2 | KDM1A 1524/4885KDM1B 753/4885DGAT1 3131/4885 |
| US-20090275566-A1 | BACE INHIBITORS | BACE1, BACE2, APP | KDM1A 1122/4885KDM1B 1197/4885DGAT1 2221/4885 |
| US-20120295900-A1 | 1,3-OXAZINES AS BACE 1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | KDM1A 1943/4885KDM1B 1938/4885DGAT1 2030/4885 |
| US-20120238548-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN2 | KDM1A 1414/4885KDM1B 858/4885DGAT1 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.